Icecure Medical Ltd
ICCM
Company Profile
Business description
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Contact
7 Haeshel Street
Southern Industrial Park
PO Box 3163
Caesarea3079504
ISRT: +972 46230333
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
66
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.70 | 14.60 | 0.16% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,077.23 | 588.64 | 1.21% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,575.18 | 9.88 | -0.04% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,865.13 | 1,090.49 | 2.07% |
| NZX 50 Index | 13,556.87 | 139.70 | 1.04% |
| S&P 500 | 6,875.62 | 78.76 | 1.16% |
| S&P/ASX 200 | 8,851.70 | 15.80 | 0.18% |
| SSE Composite Index | 4,114.92 | 2.02 | -0.05% |